Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Minerva Neurosciences is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $2.21 |
|---|---|
| 52-week range | $1.26 - $15.27 |
| 50-day moving average | $2.67 |
| 200-day moving average | $4.50 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.19 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.21 from 2023-01-26
| 1 week (2023-01-20) | 13.33% |
|---|---|
| 1 month (2022-12-27) | -5.96% |
| 3 months (2022-10-27) | -22.73% |
| 6 months (2022-07-27) | -12.65% |
| 1 year (2022-01-26) | 202.24% |
|---|---|
| 2 years (2021-01-27) | -31.37% |
| 3 years (2020-01-27) | 8.18 |
| 5 years (2018-01-26) | 6.6 |
| Gross profit TTM | $-16,838,947 |
|---|---|
| Return on assets TTM | -20.93% |
| Return on equity TTM | -675.09% |
| Profit margin | 0% |
| Book value | $-2.67 |
| Market capitalisation | $11.7 million |
TTM: trailing 12 months
We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.
Minerva Neurosciences's shares were split on a 1:8 basis on 20 June 2022. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Minerva Neurosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Minerva Neurosciences shares which in turn could have impacted Minerva Neurosciences's share price.
Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $1.26 up to $15.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is -0.0687. This would suggest that Minerva Neurosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Minerva Neurosciences has bucked the trend.
Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
